Medication info
Glicenta Duo Extended-Release Tablet 5/1000 mg (Linagliptin, Metformin Hydrochloride)

Glicenta Duo Extended-Release Tablet 5/1000 mg (Linagliptin, Metformin Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletLinagliptin Micronized›5mg / 1 tablet
Manufacturer / importer
Aju Pharmaceutical Co., Ltd.
Appearance
This medication is a white, oval-shaped extended-release film-coated tablet.
Packaging
30 tablets/bottle, 30 tablets/box [(6 tablets/PTPX5)]
Approval status
Active

MFDS item code 202400634 · Approved 2024.03.25 · Insurance code 654006190

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with a meal, preferably with the evening meal. Take 1 tablet of this drug 5/1000 mg extended-release tablet once daily. Patients taking this drug 2.5/1000 mg extended-release tablet should take 2 tablets together once daily. 1. If the patient is not currently being treated with metformin: The initial dose of this drug is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg; the dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. If the patient is being treated with metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea or metformin and insulin, the initial dose of this drug should be considered as a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored, and dosage adjustments should be made as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should be the current doses of linagliptin and extended-release metformin hydrochloride. No dosage adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other conditions that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this drug must be discontinued immediately.

Ingredients

Manufacturer
Aju Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication is used to help control blood sugar levels in patients with type 2 diabetes. Linagliptin and metformin work together to complement dietary and exercise therapies. This helps manage blood sugar levels more effectively and contributes to preventing complications by improving blood sugar control. When used safely, it will greatly assist in blood sugar management.

How to take

Adult dose

In antidiabetic therapy, the dose of this drug should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and metformin hydrochloride extended-release 2000 mg. This drug should be taken once daily with a meal, preferably with the evening meal. Take 1 tablet of this drug 5/1000 mg extended-release tablet once daily. Patients taking this drug 2.5/1000 mg extended-release tablet should take 2 tablets together once daily. 1. If the patient is not currently being treated with metformin: The initial dose of this drug is a total daily dose of linagliptin 5 mg and metformin hydrochloride 1000mg; the dose of metformin hydrochloride may be gradually increased up to the maximum recommended daily dose of 2000 mg. 2. If the patient is being treated with metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea or metformin and insulin, the initial dose of this drug should be considered as a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's current dose. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored, and dosage adjustments should be made as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should be the current doses of linagliptin and extended-release metformin hydrochloride. No dosage adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other conditions that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this drug must be discontinued immediately.

Precautions

This medication helps regulate blood sugar levels. However, there is a rare risk of developing a serious condition called lactic acidosis, so caution is needed. Patients with impaired kidney function or liver problems, as well as those with heart conditions such as acute myocardial infarction or heart failure, should not take this medication. Additionally, it should be avoided in cases of acute infections, dehydration, severe trauma, or conditions that may affect kidney function. Patients with allergies to any ingredient in this medication or those with type 1 diabetes should also not use it. There is a risk of low blood sugar, so caution is necessary when used in conjunction with other medications that can induce hypoglycemia, such as sulfonylureas or insulin. The risk of lactic acidosis may also increase if blood sugar is not well controlled, or if there are prolonged fasting periods, excessive alcohol consumption, liver function impairment, or heart disease. Kidney function must be tested before taking this medication and should be monitored regularly. Particularly elderly or patients with decreased kidney function need to be more cautious. If iodinated contrast agents are used for radiological tests, this medication should be stopped before and after the test, and resumed only after kidney function has recovered. Patients scheduled for surgery should discontinue this medication 48 hours prior to the procedure and restart it once kidney function has recovered afterwards. During the course of taking this medication, acute pancreatitis or skin blistering similar to dermatitis herpetiformis may occur; if these symptoms occur, consult a doctor immediately. When taking this medication, do not crush or chew the tablets; swallow them whole, and while the tablet shell may come out in the stool, this is normal. Additionally, this medication may lower vitamin B12 levels, so if taken for a prolonged duration, it is advisable to check vitamin B12 status through blood tests. When taking this medication with other medications, interactions may occur, so be sure to inform your doctor or pharmacist of any other medications being taken. Use during pregnancy or breastfeeding is not recommended, and patients planning to become pregnant should consult their healthcare provider. Safety in children has not been established, so pediatric use is discouraged. Elderly patients are at a higher risk for decreased kidney function, so dosage adjustments and regular kidney function tests are necessary. In the event of overdose, measures should be taken to remove the medication from the gastrointestinal tract, and if necessary, treatments such as dialysis may be required. Lastly, this medication should be kept out of reach of children, stored in a dry place, and not transferred to other containers.

Side effects

Severe lactic acidosis, hypoglycemia, nasopharyngitis, hypersensitivity reactions, angioedema, urticaria, lactic acidosis, abnormal vitamin B12 absorption test results, hypoglycemic episodes, taste disorders, cough, loss of appetite, diarrhea, constipation, nausea, pancreatitis, vomiting, abdominal pain, oral ulcers, abnormal liver function tests, hepatitis, itching, erythema, rash, pemphigoid-like lesions, severe and disabling arthralgia, rhabdomyolysis, increased lipase, increased amylase, constipation, upper abdominal pain, enterocolitis, intestinal obstruction, gastroenteritis, herpes zoster, cystitis, acute pyelonephritis, bronchitis, vestibular neuronitis, sepsis, pneumonia, decreased appetite, dehydration, hyperglycemia, cerebral infarction, stuttering, Alzheimer-type dementia, chest pain, fever, facial swelling, fatigue, chronic obstructive pulmonary disease, asthma, diabetic foot disease, skin lesions, liver metastasis, acute leukemia, basal cell carcinoma, non-small cell lung cancer, malignant pericardial effusion, gastric cancer, rectal cancer, pancreatic cancer, meniscus injury, pneumoconiosis, congestive heart failure, angina, acute myocardial infarction, unstable angina, cardiac arrest, diabetic retinopathy, acute kidney injury, end-stage renal disease, acute cholangitis, acute cholecystitis, cholangitis, dizziness, kidney transplant failure, anxiety, affective disorder, insomnia, depression, contusion, bone contusion, concussion, bone fracture, hand fracture, dry eyes, glaucoma, cataracts, ocular discomfort, allergic conjunctivitis, polyuria, proteinuria, stress urinary incontinence, hematuria, hypotension, flushing, hepatic steatosis, acute cholangitis, acute cholecystitis, cholangitis, cholelithiasis, hearing loss, erectile dysfunction, goiter, anemia, nausea, gastroesophageal reflux disease, gastritis, dizziness, sensory loss, chest discomfort, asthenia, epistaxis, oropharyngeal pain, voice disorders, allergic rhinitis, exertional dyspnea, wet cough, rhinorrhea, pulmonary mass, arthralgia, osteoporosis, arthropathy, musculoskeletal discomfort, myositis, myalgia, soft tissue mass, postmenopausal osteoporosis, rotator cuff syndrome, increased serum triglycerides, increased urine albumin/creatinine ratio, positive urine leukocytes, decreased hemoglobin, increased serum potassium, increased serum creatinine, increased serum creatine phosphokinase, elevated ALT, male pattern baldness, hyperhidrosis, dermatitis, anxiety, confusional state, nocturia, dermatitis, hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container that is not exposed to air or moisture. It is best kept at room temperature between 1 to 30 degrees Celsius.

Appearance and packaging

Appearance

This medication is a white, oval-shaped extended-release film-coated tablet.

Package unit

30 tablets/bottle, 30 tablets/box [(6 tablets/PTPX5)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.